Amylin Pharmaceuticals Announces Acceptance of 17 Abstracts for Publication at the American Diabetes Association Annual Meeting
May 21 2004 - 8:30AM
PR Newswire (US)
Amylin Pharmaceuticals Announces Acceptance of 17 Abstracts for
Publication at the American Diabetes Association Annual Meeting
Data Disclosure Through Symposia and Company-Sponsored Webcast SAN
DIEGO, May 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. today announced that data featuring its two late-stage
diabetes drug candidates, exenatide (synthetic exendin-4) and
SYMLIN(R) (pramlintide acetate) will be presented at the 64th
Annual Scientific Sessions of the American Diabetes Association
(ADA) being held in Orlando, Florida from June 4 - 8, 2004. The
meeting is one of the largest for endocrinologists and other health
care professionals involved in diabetes research and the delivery
of diabetes care. Additionally, three scientific symposia and a
company-sponsored webcast will be held during the meeting.
Abstracts for the event can be found on the ADA's website at
http://www.diabetes.org/am04. Amylin has provided an educational
grant to support a symposium entitled, "Insulin & Amylin:
Clinical Studies Exploring the Metabolic Impact of Multihormonal
Therapy." The chair of the event will be Dr. Harold Lebovitz,
Professor of Medicine at the SUNY Health Science Center - Brooklyn.
Presentations will be given by Dr. Robert Rizza, Professor of
Medicine at the Mayo Clinic College of Medicine in Rochester,
Minnesota, Dr. Steven Edelman, Professor of Medicine at the
University of California San Diego, and Dr. Matt Riddle, Professor
of Medicine, Head of the Section of Diabetes at Oregon Health &
Science University. The symposium will be held on Saturday, June
5th from 5:30 AM to 7:45 AM Eastern Time. Amylin and Eli Lilly and
Company have provided an educational grant to support a symposium
entitled, "Mimicking the Effects of GLP-1: Metabolic Control for
Type 2 Diabetes at Multiple Sites of Action." The chair of the
event will be Dr. Dan Drucker, Director, Banting and Best Diabetes
Centre, University of Toronto, Toronto General Hospital.
Presentations will be given by Dr. Drucker, Dr. Charles Burant,
Associate Professor of Internal Medicine and Molecular and
Integrative Physiology, University of Michigan, and Dr. Robert
Ratner, Professor of Medicine, Georgetown University School of
Medicine. The symposium will be held on Monday, June 7th from 5:30
AM to 7:45 AM Eastern Time. Amylin and Eli Lilly and Company have
also provided an educational grant to support a symposium entitled,
"Progress in Caring for Diabetes: Emerging Treatment Options." The
chair of the event will be Dr. Harold Lebovitz, Professor of
Medicine at the SUNY Health Science Center - Brooklyn.
Presentations will be given by Dr. Lebovitz, Dr. Steven Edelman,
Professor of Medicine at the University of California San Diego,
and Dr. James R. Gavin, III, President and Professor of Medicine at
the Morehouse School of Medicine. The symposium will be held on
Friday, June 4 from 6:00 PM to 9:30 PM Eastern Time. Amylin will be
conducting a webcast reviewing the information presented at the ADA
on Sunday, June 6, 2004 at 8:00 PM Eastern Time from the Loews
Royal Pacific Resort in Orlando. The live presentation will be
webcast, and a recording will be made available following the
event. The webcast and recording will be accessible through
Amylin's corporate website, located at http://www.amylin.com/. To
access the live webcast, please log on to Amylin's site
approximately fifteen minutes prior to the presentation to register
and download any necessary audio software. ABSTRACTS BEING
PRESENTED AT THE ADA: 1. Late Breaker: Effects of Exenatide
(Synthetic Exendin-4) on Glycemic Control and Weight Over 30 Weeks
in Metformin-Treated Patients With Type 2 Diabetes (oral and
poster) 2. Late Breaker: Effects of Exenatide (Exendin-4) on
Glycemic Control and Weight in Patients With Type 2 Diabetes
Treated With Metformin and a Sulfonylurea (poster) 3. Effect of
Exenatide (Exendin-4) on Glycemic Control and Safety Over 30 Weeks
in Sulfonylurea-Treated Patients with Type 2 Diabetes (oral) 4.
Effects of Exenatide on First and Second Phase Insulin Secretion in
Response to Intravenous Glucose in Subjects with Type 2 Diabetes
(oral) 5. Twenty-Eight Day Dose-Response Study with Exenatide
(Synthetic Exendin-4) in Subjects with Type 2 Diabetes Treated with
Metformin or with Diet and Exercise (Poster) 6. Effect of Injection
Site on Relative Bioavailability of Exenatide (Synthetic
Exendin-4). (Poster) 7. Exenatide Does Not Cause Pancreatic Islet
Cell Proliferative Lesions in Rats and Mice Following 2-year
Exposure (Poster) 8. Effect of Systemic 28-Day Exposure to
Exenatide (Synthetic Exendin-4) on Food Intake and Body Weight in
High Fat-Fed Rats (Poster) 9. Effects of Pramlintide on
Postprandial Glucose Excursions and Measures of Oxidative Stress in
Patients with Type 1 Diabetes (oral) 10. Effect of Pramlintide on
Ad-libitum Food Intake in Obese Subjects and Subjects with Type 2
Diabetes: A Randomized, Double-Blind, Placebo-Controlled,
Cross-Over Study (oral) 11. Effects of Pramlintide on the Magnitude
and Speed of Postprandial Blood Glucose Fluctuations in Patients
With Type 1 Diabetes (Poster) 12. Patients With Type 1 Diabetes:
Perceptions Associated With Pramlintide as an Adjunctive Treatment
to Insulin (Poster) 13. Assessing Glucose Variability Using CGMS in
Pramlintide and Placebo-Treated Subjects With Type 1 Diabetes
Mellitus (poster) 14. Pramlintide Pharmacokinetics in Type 1 and
Type 2 Diabetes: Effects of Injection Site, Needle Length and Body
Size (Poster) 15. Involvement of the Area Postrema in
Nutrient-Stimulated Insulin Secretion in Rats. (Poster) 16. Amylin
Potently Inhibits Ghrelin Secretion in Rats (Poster) 17. Effect of
PYY [3-36] on Exocrine Pancreatic Secretion and Gallbladder
Emptying in Rats (Publication Only) Amylin Pharmaceuticals is a
biopharmaceutical company dedicated to developing innovative
medicines to improve the lives of people with metabolic diseases.
Amylin's two latestage, first-in-class diabetes product candidates
-- SYMLIN(R) (pramlintide acetate) and exenatide (synthetic
exendin-4) -- are being developed to address the global epidemic of
diabetes. Amylin has a strategic alliance with Eli Lilly and
Company for the co-development and global commercialization of
exenatide, and an extended release formulation, exenatide LAR.
Building on its experience in the diabetes field, Amylin is
developing candidates for cardiovascular disease and obesity by
utilizing its research experience with the metabolic properties
common to all three conditions. Further information on Amylin and
its pipeline in metabolism is available at http://www.amylin.com/.
This press release contains forward-looking statements, which
involve risks and uncertainties. Actual results could differ
materially from those forward-looking statements discussed in this
press release. Amylin cannot assure you that current or future
clinical trials will confirm preliminary results or that SYMLIN,(R)
exenatide, or PYY [3-36] will receive regulatory approvals or prove
to be commercially successful. These and additional risks and
uncertainties are described more fully in Amylin's Form S-3
recently filed with the SEC. Please note that the symposium and
abstract titles listed above are intended to provide a brief
description of some of the primary data in the presentations and
should not be read as a complete representation of the data being
presented. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark
G. Foletta, Vice President, Finance and Chief Financial Officer of
Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site:
http://www.diabetes.org/am04 Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024